PMID- 24793016
OWN - NLM
STAT- MEDLINE
DCOM- 20150113
LR  - 20211021
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 35
IP  - 8
DP  - 2014 Aug
TI  - ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with 
      uterine cervical carcinoma.
PG  - 7575-86
LID - 10.1007/s13277-014-1990-1 [doi]
AB  - Metalloproteinase activities of a disintegrin and metalloproteinase 17 (ADAM17), 
      amphiregulin (AREG), extracellular matrix metalloproteinase inducer (EMMPRIN), 
      and matrix metalloproteinases (MMPs) are involved in tumor biology. In patients 
      with uterine cervical carcinoma, the expression and prognostic significance of 
      ADAM17 remain to be fully elucidated. The expression of ADAM17, AREG, EMMPRIN, 
      phospho-epidermal growth factor receptor (p-EGFR), phospho-extracellular 
      signal-regulated kinase (p-ERK), MMP-2, and MMP-9 was assessed by 
      immunohistochemistry and/or Western blotting from cervical carcinoma cell lines, 
      SiHa and HeLa cells, and cervical carcinoma tissues. AREG activity was measured 
      by ELISA assay. The correlation of ADAM17, AREG, EMMPRIN, and MMP-9 expression 
      with patients' survival rates was assessed by Kaplan-Meier and Cox regression 
      analyses. RNA interference (RNAi) experiment was performed using small 
      interfering mRNA to ADAM17 and EMMPRIN. ADAM17, EMMPRIN, and MMP-9 protein 
      content was overexpressed in cervical carcinoma tissues compared with normal 
      cervical tissues (P < 0.05). Strong expression of ADAM17, AREG, EMMPRIN, and 
      MMP-9 was significantly associated with stages, lymph node metastasis, 
      differentiation, and parametrium invasion (P < 0.05). Overexpression of ADAM17, 
      AREG, EMMPRIN, and MMP-9 was significantly correlated with short progression-free 
      survival and overall survival (P < 0.05). Multivariate analysis suggested that 
      lymph node metastasis, parametrium invasion, and ADAM17 expression were 
      independent prognostic indicators for cervical cancer. ADAM17 RNAi decreased 
      EMMPRIN, p-EGFR, p-ERK, MMP-2, and MMP-9 proteins in SiHa and HeLa cells. ELISA 
      assay revealed that AREG activity was stimulated by ADAM17 and was reversed by 
      ADAM17 RNAi in SiHa and HeLa cells. Our data suggest that the increased 
      expression of ADAM17 in cervical cancer is significantly associated with 
      aggressive progression and poor prognosis. ADAM17 may be a molecular marker for 
      predicting the progression and prognosis in cervical cancer.
FAU - Xu, Qin
AU  - Xu Q
AD  - Department of Gynecology, Fujian Provincial Cancer Hospital, Fuzhou, China.
FAU - Ying, Mingang
AU  - Ying M
FAU - Chen, Guilin
AU  - Chen G
FAU - Lin, Ang
AU  - Lin A
FAU - Xie, Yunqing
AU  - Xie Y
FAU - Ohara, Noriyuki
AU  - Ohara N
FAU - Zhou, Dongmei
AU  - Zhou D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140504
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (AREG protein, human)
RN  - 0 (Amphiregulin)
RN  - 0 (BSG protein, human)
RN  - 0 (EGF Family of Proteins)
RN  - 136894-56-9 (Basigin)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 3.4.24.- (ADAM Proteins)
RN  - EC 3.4.24.24 (MMP2 protein, human)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - EC 3.4.24.86 (ADAM17 Protein)
RN  - EC 3.4.24.86 (ADAM17 protein, human)
SB  - IM
MH  - ADAM Proteins/*physiology
MH  - ADAM17 Protein
MH  - Adult
MH  - Aged
MH  - Amphiregulin
MH  - Basigin/*physiology
MH  - EGF Family of Proteins/metabolism
MH  - ErbB Receptors/physiology
MH  - Extracellular Signal-Regulated MAP Kinases/physiology
MH  - Female
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Matrix Metalloproteinase 2/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Uterine Cervical Neoplasms/metabolism/*mortality/pathology
EDAT- 2014/05/06 06:00
MHDA- 2015/01/15 06:00
CRDT- 2014/05/06 06:00
PHST- 2013/12/18 00:00 [received]
PHST- 2014/04/17 00:00 [accepted]
PHST- 2014/05/06 06:00 [entrez]
PHST- 2014/05/06 06:00 [pubmed]
PHST- 2015/01/15 06:00 [medline]
AID - 10.1007/s13277-014-1990-1 [doi]
PST - ppublish
SO  - Tumour Biol. 2014 Aug;35(8):7575-86. doi: 10.1007/s13277-014-1990-1. Epub 2014 
      May 4.